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ABSTRACT 
Walker, S.E. and Anver, M.R., 1983. High incidence of neoplasms in female 
NZB/NZW mice treated with pulse doses of cyclophosphamide. Vet. Immunol. 
Immunopathol., 5: 97-104. 
The immunosuppressive properties of cyclophosphamide prevent formation of 
anti-DNA antibodies and prolong l ifespans in autoimmune NZB/NZW mice, an animal 
model of systemic lupus erythematosus. In the current study, NZB/NZW mice were 
treated with weekly doses of cyclophosphamide to determine i f  in termi t tent  
pulses of the drug were e f fec t ive  therapy. Li fe- long treatment with cyclophos- 
phamide, 56 mg/kg/week, was started at the mean age of 6 weeks; results were 
compared with sal ine- in jected control mice. Pulse therapy with cyclophospha- 
mide suppressed anti-DNA antibody levels,  prevented severe olomerulonephritis 
and prolonged longevity. Seventeen of 19 treated mice developed neoplasms; 7 
of these immunosuppressed animals had 2 to 4 separate neoplasms. Examination 
of ea r l i e r  studies in this laboratory in which NZB/NZW mice were treated each 
day with cyclophosphamide showed that da i ly  and weekly therapeutic regimens 
had s imi lar  immunosuppressive and oncogenic ef fects.  
INTRODUCTION 
Female New Zealand Black/New Zealand White (NZB/NZW) mice spontaneously de- 
velop antibodies to DNA (anti-DNA) (Steinberg et a l . ,  1969) and immune complex 
glomerulonephritis (Lambert and Dixon, 1968), and they are accepted as models 
of systemic lupus erythematosus. F i f t y  percent of female NZB/NZW mice die with 
renal fa i lu re  at the age of I0 months (Howie and Helyer, 1968). 
A series of experiments in this laboratory showed that prolonged da i ly  ad- 
ministrat ion of the potent a lky lat ing agent cyclophosphamide, in doses ranging 
from 5.7 to 16 mg/kg, suppressed autoimmunity and prolonged l i fespans in hybrid 
New Zealand females. An unfortunate complication of therapy was the appearance 
of neoplasms in 89 to 100% of treated mice (Walker and Bole, 1973; Walker and 
Anver, 1978). 
Because long-term 
sulted in a high inci  
therapy might modify 
and oncogenic potenti 
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anti-DNA, prevented glomerular disease and prolonged l i fespans. Neoplasms 
appeared in 89% of treated mice. In termi t tent  cyclophosphamide therapy was 
therefore s im i la r  to dai ly  therapy. Pulse doses did not modifytheoncogenic 
properties of cyclophosphamide. 
METHODS 
Animals 
Breeding and maintenance of New Zealand Black (NZB), New Zealand White (NZW), 
and NZB/NZIJ mice were described in another publ icat ion (Walker and Bole, 1973). 
Hybrid mice used in this study were produced by mating NZB females and NZW 
males. These animals were maintained in f a c i l i t i e s  accredited by the American 
Association for  Accreditat ion of Laboratory Animal Care. 
Treatment protocol 
Cyclophosphamide (Mead Johnson and Co., Evansvi l le,  IN, U.S.A.), 56 mg/kg 
in O.l ml volume, was dissolved in s t e r i l e  0.15 rl NaCl immediately before use 
and given weekly by subcutaneous in ject ion to 22 female NZB/NZW mice (mean a~e 
6 weeks + l SEM). Fifteen female control mice with mean age I I  weeks (+_ I) 
were injected dai ly  with O.l ml 0.15 ~I NaCl. Inject ions continued unt i l  spon- 
taneous death. Control mice were entered into the study 3 months a f te r  the 
treated groups began receiving cyclophosphamide. Because therapy prolonged 
l i fespans, a l l  cyclophosphamide-treated mice were a l ive  when sal ine in ject ions 
began in control animals. 
Blood samples were col lected from the o rb i ta l  plexus before treatement and 
a f te r  24 and 52 weeks of treatment. Treated and control animals were examined 
da i ly ;  they were bled, k i l l e d  by cervical separation, and autopsied when they 
developed neoplasms or appeared moribund. 
Histo logic studies 
Complete necropsies y ie lded tissue which was f ixed,  embedded and stained 
for  l i gh t  microscopic examination using methods described e a r l i e r  (Walker and 
Bole, 1973). Severi ty of glomerulonephrit is was scored by counting numbers of 
speci f ic  abnormalit ies in 20 glomeruli in a 4-micron cross section of each kid- 
ney. I n f i l t r a t e s  of  lymphocytes around renal ar ter ies were graded on a scale of  
0 to 4+: 0 = no ce l l s ,  I+ = few ce l l s ,  2+ = cel ls surrounded 25-50% of  ar ter -  
ia l  wa l l ;  3+ = cel ls surrounded 75% of  a r te r i a l  wa l l ;  4+ = cel ls surrounded 
ent i re  a r te r i a l  wall (Walker et a l . ,  1978). 
/~mti-DNA 
Serum was stored at -20°C in sealed cap i l l a ry  tubes and tested for anti-DNA 
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antibodies using a modified Farr technique. 14C-labeled E. col i  DNA (Amersham 
Corporation, Ar l ington Heights, IL, U.S.A.) was reacted with heat- inact ivated 
mouse serum using a method described previously (Walker and Bole, 1975). In 
th is  laboratory,  values greater than 20% binding indicate the presence of  ant i -  
DNA antibodies. 
S ta t i s t i ca l  analysis 
Student's t test  was calculated as described by Snedecor and Cochran (1967). 
RESULTS 
Longevity 
Three treated mice and 2 control mice died of iat rogenic causes or were los t  
because of  auto lys is .  These animals were excluded from the study. In the con- 
t ro l  group mean longevi ty was 46 weeks ~ 4, and l i fespans ranged from 27 to 77 
weeks. The f i r s t  death in cyclophosphamide-treated mice occurred at 32 weeks of  
age; the last  animal died at the age of 94 weeks. Mean surv ival  in treated mice 
was 70 weeks ~ 4. Lifespans were prolonged s i g n i f i c a n t l y  in treated mice com- 
pared to controls (p<O.O01). 
Causes of death 
In the contro ls ,  vascu l i t i s  and severe glomerulonephrit is caused death and 
no neoplasms were found at necropsy. In contrast,  17 of  the 19 treated mice 
that were not los t  by iatrogenic death or autolysis had 1 or more neoplasms 
(Table I ) .  
The f i r s t  malignancies to appear were malignant lymphomas; 4 of these lesions 
appeared 38 to 49 weeks a f ter  the study began. Two widespread sarcomas also 
appeared r e l a t i v e l y  ear ly in the treatment period. Localized lesions in sub- 
cutaneous areas, pe lv is ,  breast, and lung appeared late in the treatment period 
a f te r  mice received therapy for 58 to 86 weeks. Two treated mice died with 
ovarian hemorrhage. 
To determine i f  cyclophosphamide administered in weekly doses was comparable 
to da i ly  therapy, mice treated with both regimes were examined for  longevi ty  
and neoplasms. Table 2 compares NZB/NZW female contro ls ,  female mice treated 
with cyclophosphamide 8 mg/kg/day in an ea r l i e r  study in th is  laboratory 
(Walker and Bole, 1973), and pulse-treated females in the current study. 
Anti-DNA antibodies 
In control mice, mean anti-DNA increased from 16% ~ 1 at the beginning of  
the study to 38% ~ 5 a f te r  24 weeks of observation, At 52 Weeks, one surv iv ing  
untreated animal had 45% DNA binding. Mean anti-DNA in terminal sera from con- 
t ro l  mice was 20% ~ I .  In termi t tent  therapy wi th cyclophosphamide suppressed 
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TABLE 1 
Neoplasms in female IIZB/rlZW mice treated with weekly doses of cyclophospha- 
mide, 56 mg/kg 




4 Malignant lymphoma 28-49 
1 Fibrosarcoma 50 
1 Sarcoma 63 
1 Malignant lymphoma a 70 
Local Neoplasms 
Mammary carcinoma, sebaceous gland 
adenoma, pulmonary adenoma 
Sguamous cel l  carcinoma 
Subcutaneous sarcoma 
Mammary carcinoma, squamous cel l  
carcinoma, pulmonary adenoma 
Mammary carcinoma, sarcoma, hemangio- 
sarcoma, pulmonary adenoma 
Mammary carcinoma, fibrosarcoma, 
pulmonary adenoma 
Sarcoma (pelv is)  









aThis mouse also had a pulmonary adenoma. 
TABLE 2 
Comparison of longevi ty and neoplasms in female NZB/NZW mice treated with 
da i ly  and weekly doses of cyclophosphamide 
Mice with 
Treatment Mean, range Mice with Mult ip le 
groups a longevi ty Neoplasms Neoplasms 
(wks) (%) (%) 
Class i f icat ion of Neoplasms b 
(% of tota l  neoplasms) 
Ly C a r c  Sarc Other 
0 46 (24 - 103) 3 0 I00 0 0 0 
8 77 (58 - 108) I00 22 42 42 8 8 
56 70 (32 - 94) 89 37 17 21 34 28 
aTreatment groups; 0 = control mice injected with sal ine;  8 = cyclophosphamide, 
8 mg/kg/day; 56 = cyclophosphamide, 56 mg/kg/week. Each group contained 9-19 
mice. 
bAbbreviations: Ly = lymphoma; Carc = carcinoma; Sarc = sarcoma. 
I01 
anti-DNA during the f i r s t  year of the study, rlean DNA binding values were 
21% + 1 pretreatment, 19 + 1 a f ter  24 weeks, and 20 + 1 a f te r  52~eeks of t reat -  
ment. At the 24-week i n te rva l ,  anti-DNA in treated mice was decreased s i gn i f i -  
can-tly compared to controls (p<O.O01). In 15 treated mice with terminal serum 
avai lable for  test ing,  mean anti-DNA was 30 ~ 2. 
Renal lesions 
Severe glomerulonephrit is in control mice accounted for the mean glomerular 
lesion score of 53 ~ 2; 69% of these animals had a r t e r i t i s  invo lv ing renal 
vessels, and heavy 3-4+ pe r ia r te r i a l  i n f i l t r a t e s  were found in 47% of control 
kidneys. The protect ive e f fec t  of  weekly doses of cyclophosphamide was evident 
in treated mice, whose mean glomerular lesion score was suppressed s i g n i f i c a n t l y  
to 22 ~ 2 (compared to control mice, p<O.O01). Renal vascu l i t i s  was not pre- 
sent in treated animals, and scant pe r ia r te r i a l  lymphocytes graded I+ were iden- 
t i f i e d  in 16% of treated mice. 
DISCUSSION 
The ea r l i es t  reports of favorable outcome in autoimmune NZB/NZW mice treated 
with cyclophosphamide (Russell et a l . ,  1966; Russell and Hicks, 1968) were con- 
firmed by other invest igators who used in te rmi t ten t  or da i l y  dose regimes. 
Weekly in ject ions of 1.8 mg cyclophosphamide suppressed glomerulonephrit is and 
prolonged longevi ty in female NZB/NZW hybrids (Russell and Hicks, 1968; Casey, 
1968; Horowitz et a l . ,  1969). In subsequent experiments, therapeutic e f fec t i ve-  
ness was achieved with doses ranging from 50 to 240 mg/kg, administered at in-  
tervals of 7 days to 1 month (Hahn et a l . ,  1975; Morris et a l . ,  1976; Levy et 
a l . ,  1978). Autoimmunity was also suppressed with da i l y  doses of cyclophospha- 
mide, 5 to 8 mg/kg; administrat ion of equivalent doses in weekly, lO-day, or 
monthly schedules had s im i la r  protect ive ef fects (Hahn et a l . ,  1975; Morris 
et a l . ,  1976). 
The oncogenesis which complicates cyclophosphamide therapy in New Zealand 
hybrids was noted in the ear ly report of Russell and Hicks (1968), when neo- 
plasms were discovered in 29% of animals receiving prolonged therapy with 
cyclophosphamide, 1.8 mg/week. Subsequent descript ions of in te rmi t ten t  cyclo- 
phosphamide therapy in female NZB/NZW mice mentioned tumors in 2 to 86% of 
treated animals, compared to tumor occurrence of 0 to 3% in controls (Casey, 
1968; Horowitz et a l . ,  1969; Hahn et a l . ,  1975; Morris et a l . ,  1976). In one 
report malignancies were found in 72% of  mice receiving da i ly  therapy, whereas 
55% of mice treated on a weekly basis had tumors (Hahn et a l . ,  1975). This 
information suggested that da i ly  treatment had a greater oncogenic potent ia l  
compared to weekly therapy. However, careful determination of  the true in -  
cidences of neoplasms in da i l y  versus in te rmi t ten t  treatment groups was hindered 
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because some animals were k i l l e d  at in tervals before neoplasms appeared, and 
other mice died spontaneously and were not necropsied. 
In the current study, mice were examined carefu l ly  on a dai ly basis and only 
2 treated animals were lost  because of autolysis and iatrogenic death. Re- 
l i ab le  information concerning causes of death was therefore avai lable in 91% 
of mice receiving pulse therapy, and the favorable therapeutic outcome and 
undesirable oncogenic properties of  the weekly dose regime were ver i f i ed .  
The et io logy of neoplasms in cyclophosphamide-treated NZB/NZW mice is not 
known. Age-related loss of cel l  mediated immune defenses (Krakauer et a l . ,  
1976) and the presence of oncogenic C-type viruses in New Zealand mice (Gazdar 
et a l . ,  1972; Croker et a l . ,  1974) are important factors which may contr ibute 
to oncogenesis in these immunologically flawed animals. Although NZB/NZ~J mice 
may be predisposed to develop neoplasms, malignancies were not common in females 
in the Ann Arbor colony because ear ly death with renal fa i l u re  obscured the true 
occurrence of neoplasms (Walker and Bole, 1973; Walker and Anver, 1978). 
Results of therapeutic experiments in this laboratory supported the theory 
that increased longevity was associated with oncogenesis in female NZB/NZW hy- 
brids. A r t i f i c i a l  prolongation of l i f e  in NZB/NZW females treated with varied 
agents such as f ren t i zo le  (Walker et a l . ,  1982) and high-dose hydrocortisone 
(Walker et a l . ,  1978) was associated with tumor incidence of 29 to 76%. Despite 
these f indings, other evidence suggests that therapy with cyclophosphamide may 
contr ibute d i rec t l y  to oncogenesis in hybrid New Zealand mice. Female NZB/NZW 
mice treated with a high dose of cyclophosphamide (16 mg/kg/day) have e a r l i e r  
appearance of  neoplasms compared to NZB/NZW females treated with 8 mg/kg/day 
(Walker and Anver, 1979). A therapeutic study u t i l i z i n g  long- l ived NZB/NZW 
males provided addi t ional  evidence that cyclophosphamide is a carcinogen. Long- 
term administrat ion of  cyclophosphamide, 8 mg/kg/day, was associated with a 
tumor incidence of 89%. In contrast, neoplasms were observed in 13% of male 
controls (Walker and Bole, 1973). 
The current study confirms the oncogenic potent ia l  of cyclophosphamide in 
female NZB/NZW mice. Longevity was s imi lar  in mice treated with weekly and 
da i ly  cyclophosphamide, and the same pattern of neoplasia was observed in both 
groups. Malignant lymphomas and sarcomas were found re l a t i ve l y  ear ly,  a f te r  28 
to 70 weeks of treatment. Later in the course of therapy (50 to 86 weeks) 
local ized neoplasms appeared as so l i t a ry  or mult ip le lesions. Lymphomas formed 
a greater percentage of the tota l  number of neoplasms in mice treated da i l y ,  and 
sarcomas were the most common lesions in mice receiving weekly therapy. Despite 
these minor di f ferences, the s imi lar  results of weekly and dai ly  treatment sup- 
port the conclusion that treatment in tervals are of minor importance in de- 
termining outcome in female NZB/NZW mice treated with cyclophosphamide. 
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